Promising
Ipamorelin
The prediction game
Call it: rising or fading?
Where does Ipamorelin stand 12 months from now? Lock your call with a confidence level. When the window closes, the Brier rule scores your calibration: right and confident earns the most, wrong and confident costs the most. Points and a leaderboard spot are the whole prize. No stakes, no money.
One call per intervention. It locks the moment you submit: no edits, no cancels. It resolves when the 12-month window closes.
The Crowd’s Call
Rising or fading over the next 12 months? Lock your call and find out if you saw it coming.
Community Signal
No weigh-ins yet. Be the first and set the early signal.
Evidence
Evidence grade: C (mixed evidence)
Graded from the strength of the published research, independent of any verdict on this page.
Evidence Anchor
BioHarmony 6.2/10
Ipamorelin sits at neutral because it pairs a clean, well-understood mechanism with an almost empty human outcomes file. If you want a selective growth-hormone secretagogue, accept that the popular benefits are unproven in people, and can monitor IGF-1 and glucose with quality material, it is a reasonable, low-drama tool. If you expect evidence-backed fat loss or recovery, the data is not there, and the one human efficacy trial failed, per Beck 2014. The biggest real-world risk is not the molecule; it is sourcing unregulated peptides. ✅ Best for: Researchers and clinicians who value receptor selectivity and a mild side-effect profile over proven outcomes. Older adults with low baseline growth-hormone output, who tend to respond more. People chasing the most consistently reported effect, better sleep, who will judge it on their own response over a few weeks. Users who already have training, protein, and sleep dialed in and want a low-suppression add-on. Anyone who can obtain pharmaceutical-grade material with a third-party certificate of analysis and will track IGF-1 and fasting glucose. ❌ Avoid if: You have active or hormone-sensitive cancer, since growth-hormone and IGF-1 signaling can promote proliferation. You are pregnant or breastfeeding, with no safety data. You have uncontrolled diabetes or insulin resistance, because growth hormone opposes insulin. You have congestive heart failure or fluid-overload risk. You compete in tested sport, since secretagogues are banned at all times under WADA S2. You cannot verify source quality, because contamination and immunogenicity from aggregated research-chemical peptides may exceed the intrinsic pharmacological risk.
Read the full BioHarmony report
My score and my verdict: one signal of three, never the whole answer.
Momentum
Signals begin with Edition 2
Direction needs two weekly snapshots to compare, so the arrows stay off until the next edition. Attention tracking is already running.
In the news this week: Jay Campbell.
Momentum = how fast attention is rising across search, Reddit, PubMed, podcasts, and curated industry newsletters this week; it can flag an item as Overhyped/Fading, but it never overrides the evidence behind Proven. How momentum works.
- Ring
- Promising
- Trend
- Begins with Edition 2
- Momentum
- 6.5%
- BioHarmony Score
- 6.2/10
- Last Updated
- Jul 2, 2026
Sources
- BioHarmony score
- Search trend delta
- Reddit velocity
- PubMed publication count
- Podcast mention frequency
- Curated newsletter mentions
The score anchors the ring; the other five drive momentum, which can nudge the ring by one step at most. How placement works.
Weigh In
Your input feeds the community signal shown beside my verdict. It informs the board and it never sets the score by itself. How community input works.
New voice here? We send a one-tap verification link so every entry comes from a real person. Signed-in members skip this.